Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
© Drake and Grüning 2015
Published: 2 October 2015
Neuroendocrine tumours (NETs) are a heterogeneous group with significant variation in morphological characteristics and functional behaviour. This poses challenges in terms of both biochemical and imaging assessment.
Somatostatin receptor (sst) overexpression is documented in several malignancies. The sst subtype 2 (sst2) is overexpressed in NETs  and can be targeted for both somatostatin receptor scintigraphy and therapy.
In-111-octreotide (Octreoscan), a gamma imaging sst agent, binds with relatively high affinity to sst 2.This has good overall sensitivity in the detection of NETs (80-100%) . However, sensitivity varies according to tumour type, grade, and location (e.g. sensitivity 24% in insulinomas) .
PET agents such as Ga-68-DOTA-labelled somatostatin analogues have been developed with higher receptor affinity when compared to gamma-based agents. This leads to improved target-to-background ratio and provides the improved imaging characteristics inherent of PET tracers. A 2012 meta-analysis demonstrated pooled sensitivity and specificity in detecting NETs of 93% and 91%, respectively  with higher detection rates compared to conventional sst imaging .
Whilst other PET tracers such as F-18-DOPA have shown utility and higher sensitivity than conventional sst scintigraphy, their role is limited to problem solving at present. F-18-FDG can, however, provide prognostic information with patients showing uptake having a progression free survival of 0% at 2 years compared with 75±10% in those without uptake .
Peptide receptor radionuclide therapy (PRRT) utilises primarily beta-emitting radioisotopes such as Lu-177 and Y-90 linked to somatostatin analogues such as DOTATATE and DOTATOC. Whilst phase 3 data comparing PRRT with other therapies is awaited, treatment with Y-90 and Lu-177 PRRT has been shown to have response rates of approximately 80% and to confer a survival advantage over historical controls . Unsurprisingly, extensive hepatic involvement is an adverse factor for progression free survival, whereas high tumour uptake in pre-therapy imaging confers prolonged survival .
Due to the differences in beta particle energy and path length, it has been postulated that Lu-177 PRRT would be best suited to smaller tumour volumes compared with Y-90 which emits a more energetic particle with longer path length. Kunikowska and colleagues have now demonstrated that overall survival is significantly higher in patients treated with combination Y-90/Lu-177-DOTATATE compared with Y-90-DOTATATE alone .
Research into the role of sst antagonists is relatively new. Several studies have shown a significantly greater number of binding sites for antagonists when compared to agonists such as Lu-177-DOTATATE. Pilot studies have shown 1.7-10.6 times higher tumour dose with the antagonist Lu-177-DOTA-JR11 when compared to Lu-177-DOTATATE . Encouraging results have also been obtained with the use of radiosensitising chemotherapeutic agents administered together with PRRT. A phase 2 study evaluating capecitabine with Lu-177-octreotate demonstrated a response rate of 94% with no significant increase in toxicity . Further work is required, however, these advances are likely to play a significant role in the future.
- Reubi JC, Waser B, Schaer JC, et al: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001, 28: 836-846. 10.1007/s002590100541.PubMedView ArticleGoogle Scholar
- Teunissen JJM, Kwekkeboom DJ, Valkema R, et al: Nuclear Medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocrine-Related Cancer. 2011, 18: s27-s51. 10.1530/ERC-10-0282.PubMedView ArticleGoogle Scholar
- Vezzosi D, Bennet A, Rochaix P, et al: Octreotide in insulinoma patients: efficacy on hypoglycaemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2a and anti-sst5 antibodies. Eur J Endocrinology. 2005, 152: 757-767. 10.1530/eje.1.01901.View ArticleGoogle Scholar
- Treglia G, Castaldi P, Rindi G, et al: Diagnostic performance of gallium-68 somatostatin receptor PET and PET CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012, 42: 80-87. 10.1007/s12020-012-9631-1.PubMedView ArticleGoogle Scholar
- Gabriel M, Decristo C, Kendler D, et al: 68 Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumours: Comparison with Somatostatin receptor scintigraphy and CT. J Nucl Med. 2007, 48: 508-518. 10.2967/jnumed.106.035667.PubMedView ArticleGoogle Scholar
- Garin E, Le Jeune F, Devillers A, et al: Predictive Value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumours. J Nucl Med. 2009, 50: 858-864. 10.2967/jnumed.108.057505.PubMedView ArticleGoogle Scholar
- Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabelled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008, 26: 2124-2130. 10.1200/JCO.2007.15.2553.PubMedView ArticleGoogle Scholar
- Imhof A, Brunner P, Marincek N, et al: Response, survival and long -term toxicity after therapy with the radio labelled somatostatin analogue[90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011, 29: 2416-2423. 10.1200/JCO.2010.33.7873.PubMedView ArticleGoogle Scholar
- Kunikowska J, Krolicka L, Hubalewska-Dydejczyk A, et al: Clinical results of radionuclide therapy of neuroendocrine tumours with Y90-DOTATATE and tandem Y90/Lu177-DOTATATE: which is better therapy option?. Eur J Nucl Med Mol Imaging. 2011, 38: 1788-1797. 10.1007/s00259-011-1833-x.PubMedPubMed CentralView ArticleGoogle Scholar
- Wild D, Fani M, Fischer R, et al: Comparison of somatostatin receptor agonist and antagonis for peptide receptor radionuclide therapy: A pilot study. J Nucl Med. 2014, 55: 1-5. 10.2967/jnumed.112.114264.View ArticleGoogle Scholar
- Claringbold PG, Brayshaw PA, Price RA, et al: Lu177-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011, 38: 302-311. 10.1007/s00259-010-1631-x.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.